Three proof-of-concept studies evaluating INCB39110 in patients with myelofibrosis, psoriasis and rheumatoid arthritis are underway, with preliminary results expected in the second half of 2013. The results of these studies are expected to inform us as to the most appropriate indications for further development.
Source: press release, 5/02/13. http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1...
A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis
Estimated Enrollment: 95
Study Start Date: March 2012
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Source: clinical trials.gov. http://clinicaltrials.gov/ct2/show/NCT01626573?term=Incyte+Rheumatoid+ar...
Compound/Device Specialty Indication Compound Class Target
INCB-039110 Rheumatology Rheumatoid Arthritis (RA) Janus-associated Kinase Inhibitors Janus-associated Kinase
Mechanism of action: INCB-039110, a SM-inhibitor, reduces cell proliferation by disrupting the signaling of the Janus-associated kinases (JAK) pathway. Aberrant activation of the JAK-STAT pathway has been documented in a variety of autoimmune diseases and cancers.